{"symbol":"LLY","fiscalQuarter":"Q2-2026","reportDate":"2026-08-05","reportTime":"BMO","status":"upcoming","company":{"name":"Eli Lilly and Company","sector":"Health Care","industry":"Pharmaceuticals"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/LLY/earnings/Q2-2026","estimates":{"consensusEps":6.549,"consensusRevenue":20686.28,"epsLow":5.28,"epsHigh":9.08,"whisperEps":null,"numAnalysts":null},"preBrief":{"companySnapshot":"Eli Lilly and Company (LLY) is a leading pharmaceutical company focused on developing innovative treatments for various health conditions, including diabetes and cancer. With a market cap of $1,078 billion, it plays a crucial role in the healthcare sector, addressing significant medical needs and contributing to advancements in patient care.","keyMetrics":[{"name":"Earnings Per Share (EPS)","why":"EPS is a key indicator of the company's profitability and is closely watched by investors.","consensus":"$6.55"},{"name":"Revenue","why":"Revenue growth reflects the company's ability to sell its products and expand its market share.","consensus":"$20.7B"}],"lastQuarterRecap":{"summary":"In Q1 2026, Eli Lilly reported an EPS of $8.55, significantly exceeding analyst expectations of $7.06, resulting in a 9.80% stock increase the following day. The company continues to show strong performance, indicating robust demand for its products.","promises":[]},"wallStreetExpectations":{"summary":"Analysts are optimistic about Eli Lilly's upcoming earnings report, with expectations for strong EPS and revenue figures. The company has a history of beating estimates, which could lead to positive market reactions.","bullCase":"If Eli Lilly surpasses the consensus EPS of $6.55 and reports strong revenue, it could reinforce investor confidence and drive the stock higher.","bearCase":"Conversely, if the company fails to meet expectations or provides weak guidance, it could lead to a significant decline in stock price, reflecting investor disappointment."},"optionsSignal":{"impliedMove":"8.56%","context":"The options market is pricing in an 8.56% move, indicating that traders expect significant volatility around the earnings report."},"earningsTrackRecord":[{"quarter":"Q1-2026","epsSurprise":"+21.07%","reaction":"+9.80%"},{"quarter":"Q4-2025","epsSurprise":"+7.88%","reaction":"+10.33%"},{"quarter":"Q3-2025","epsSurprise":"+16.59%","reaction":"+3.81%"},{"quarter":"Q2-2025","epsSurprise":"+14.08%","reaction":"-14.14%"},{"quarter":"Q1-2025","epsSurprise":"-5.01%","reaction":"-11.66%"}],"pivotalQuestions":[{"question":"Will Eli Lilly's EPS exceed the consensus estimate of $6.55?","whyItMatters":"A strong EPS report could validate the company's growth strategy and boost investor confidence."},{"question":"What guidance will management provide regarding future revenue growth?","whyItMatters":"Future revenue guidance is crucial for understanding the company's trajectory and market positioning."}],"thesisBreakLevels":{"bullTrigger":"A reported EPS of $7.00 or higher would confirm the bull case.","bearTrigger":"An EPS below $5.50 would confirm the bear case.","context":"This quarter's performance is critical as it will determine whether Eli Lilly can maintain its growth momentum amid increasing competition."},"scenarioPlaybook":{"beatAndRaise":"If Eli Lilly beats expectations, history suggests a potential 3.77% increase in stock price, confirming the company's strong growth narrative.","inLineCautious":"If results are in line with expectations, the stock may experience a muted reaction as investors await further clarity from management.","miss":"Should the company miss estimates, history indicates an average decline of 8.97%, reflecting investor disappointment."},"whatTheStreetIsMissing":{"thesis":"The Street may underestimate Eli Lilly's ability to leverage its recent product launches, which could drive stronger-than-expected revenue growth.","supportingPoints":["The company's recent performance has shown a consistent ability to exceed EPS estimates, suggesting strong operational execution.","Options pricing indicates a significant expected move, reflecting market anticipation that could be based on positive developments not yet fully appreciated.","Historically, Eli Lilly has a 75% EPS beat rate, indicating a strong track record of outperforming expectations."],"riskToConsensus":"If the upcoming report reveals lower-than-expected demand for key products, it could challenge the current bullish sentiment."},"whatToListenFor":["Any updates on new product launches and their market reception.","Management's commentary on competitive pressures and pricing strategies.","Insights into research and development progress for upcoming therapies.","Guidance on revenue expectations for the next quarter and beyond.","Any changes in regulatory environment affecting product approvals."],"metaDescription":"Eli Lilly (LLY) reports Q2 2026 earnings August 5. Analysts expect $6.55 EPS on $20.7B revenue. Here's what to watch."}}